{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:55:21Z","timestamp":1760345721714},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1990,11,1]],"date-time":"1990-11-01T00:00:00Z","timestamp":657417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1990,11,1]],"date-time":"1990-11-01T00:00:00Z","timestamp":657417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1990,11]]},"DOI":"10.1007\/bf00198594","type":"journal-article","created":{"date-parts":[[2004,8,29]],"date-time":"2004-08-29T04:04:13Z","timestamp":1093752253000},"page":"377-379","source":"Crossref","is-referenced-by-count":4,"title":["Phase II trial of vinblastine in advanced ovarian carcinoma"],"prefix":"10.1007","volume":"8","author":[{"given":"Gregory P.","family":"Sutton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Adelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00198594_CR1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.1989.7.2.223","volume":"7","author":"GP Sutton","year":"1989","unstructured":"Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE: Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223\u2013229, 1989","journal-title":"J Clin Oncol"},{"key":"BF00198594_CR2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00000421-198308000-00008","volume":"6","author":"JT Thigpen","year":"1983","unstructured":"Thigpen JT, Lagasse L, Homesley H, Blessing JA: Cisplatinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 6:431\u2013435, 1983","journal-title":"Am J Clin Oncol"},{"key":"BF00198594_CR3","doi-asserted-by":"crossref","unstructured":"Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1989, in press.","DOI":"10.1016\/0090-8258(89)90893-7"},{"key":"BF00198594_CR4","first-page":"1","volume":"65","author":"SA Salmon","year":"1981","unstructured":"Salmon SA, Meyskens FL, Alberts DS, Soehnlen B, Young L: New drugs in ovarian cancer and malignant melanoma: In vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep 65:1\u201312, 1981","journal-title":"Cancer Treat Rep"},{"key":"BF00198594_CR5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0002-9378(83)91000-1","volume":"146","author":"EA Surwit","year":"1983","unstructured":"Surwit EA, Alberts DS, Crisp W: Multiagent chemotherapy in relapsing ovarian cancer. Am J Obstet Gynecol 146:613\u2013616, 1983","journal-title":"Am J Obstet Gynecol"},{"key":"BF00198594_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00000421-198502000-00041","volume":"8","author":"FB Stehman","year":"1985","unstructured":"Stehman FB, Ehrlich CE, Williams SD, Einhorn LH: Cisplatin, vinblastine, and bleomycin as second trial therapy in ovarian carcinoma: A pilot study of the Gynecologic Oncology Group. Am J Clin Oncol 8:27\u201331, 1985","journal-title":"Am J Clin Oncol"},{"key":"BF00198594_CR7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0090-8258(77)90007-5","volume":"5","author":"CR Stanhope","year":"1977","unstructured":"Stanhope CR, Smith JP, Rutledge F: Second trial drugs in ovarian cancer. Gynecol Oncol 5:52\u201357, 1977","journal-title":"Gynecol Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00198594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00198594\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00198594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00198594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:19:11Z","timestamp":1678558751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00198594"}},"subtitle":["A Gynecologic Oncology Group study"],"short-title":[],"issued":{"date-parts":[[1990,11]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,11]]}},"alternative-id":["BF00198594"],"URL":"https:\/\/doi.org\/10.1007\/bf00198594","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[1990,11]]}}}